Ignite Creation Date:
2024-05-06 @ 12:57 AM
Last Modification Date:
2024-10-26 @ 10:56 AM
Study NCT ID:
NCT01690468
Status:
TERMINATED
Last Update Posted:
2020-09-24
First Post:
2012-09-19
Brief Title:
PTX-200 and Carboplatin in Ovarian Cancer
Sponsor:
Prescient Therapeutics Ltd
Organization:
Prescient Therapeutics Ltd
Study Overview
Official Title:
A Phase IAIB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status:
TERMINATED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Enrollment stopped prior to Phase 1b change in strategic focus
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to determine if Triciribine TCN and carboplatin are safe and tolerable when given together and to determine if this combination of drugs can help people with recurrent ovarian cancer
Detailed Description:
The purpose of this study is to investigate the safety and tolerability and determine the maximum tolerated dose of triciribine when combined with carboplatin in women with platinum-resistant recurrent or persistent ovarian cancer The secondary objectives are to evaluate the clinical activity of carboplatin plus triciribine in women with recurrentpersistent platinum-resistant ovarian cancer by assessing response rate progression-free survival and duration of stable disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None